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ABSTRACT
Here, we identified two new molecular targets, which are functionally sufficient 
to metabolically confer the tamoxifen-resistance phenotype in human breast cancer 
cells. Briefly, ~20 proteins were first selected as potential candidates, based on 
unbiased proteomics analysis, using tamoxifen-resistant cell lines. Then, the cDNAs 
of the most promising candidates were systematically transduced into MCF-7 cells. 
Remarkably, NQO1 and GCLC were both functionally sufficient to autonomously 
confer a tamoxifen-resistant metabolic phenotype, characterized by i) increased 
mitochondrial biogenesis, ii) increased ATP production and iii) reduced glutathione 
levels. Thus, we speculate that pharmacological inhibition of NQO1 and GCLC may 
be new therapeutic strategies for overcoming tamoxifen-resistance in breast cancer 
patients. In direct support of this notion, we demonstrate that treatment with a 
known NQO1 inhibitor (dicoumarol) is indeed sufficient to revert the tamoxifen-
resistance phenotype. As such, these findings could have important translational 
significance for the prevention of tumor recurrence in ER(+) breast cancers, which 
is due to an endocrine resistance phenotype. Importantly, we also show here that 
NQO1 has significant prognostic value as a biomarker for the prediction of tumor 
recurrence. More specifically, higher levels of NQO1 mRNA strongly predict patient 
relapse in high-risk ER(+) breast cancer patients receiving endocrine therapy (mostly 
tamoxifen; H.R. > 2.15; p = 0.007).
INTRODUCTION
Drug-resistance, and the resulting treatment failure, 
are still significant clinical barriers, preventing more 
effective cancer therapy and better clinical outcomes [1]. 
For example, in ER(+) breast cancer, nearly 30% to 50% 
of these patients develop resistance to endocrine-based 
therapies, such as tamoxifen [2-4]. Tamoxifen-resistance 
reveals itself clinically as tumor recurrence or systemic 
metastasis, leading to advanced disease states and pre-
mature patient deaths [5]. Thus, endocrine-therapy 
resistance is a major determinant that significantly reduces 
the effectiveness of breast cancer therapy. As such, more 
mechanistic studies are needed to understand the molecular 
basis of tamoxifen-resistance at the molecular level [6, 
7]. Importantly, once these key drivers of the tamoxifen-
resistance phenotype are identified they may also serve as 
therapeutic targets and predictive biomarkers to identify 
high-risk patients, before they become tamoxifen-resistant 
[8, 9]. 
Here, using a combination of proteomics analysis 
and metabolic phenotyping, we identified enhanced 
mitochondrial function and oxidative stress, as key 
drivers of tamoxifen-resistance [10, 11]. In this context, 
we showed that NQO1 and GCLC, were sufficient to 
genetically confer tamoxifen-resistance in otherwise 
tamoxifen-sensitive MCF-7 cells, by enhancing their 
mitochondrial function [12, 13]. Thus, NQO1 and GCLC 
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may be i) new prognostic biomarkers, ii) novel therapeutic 
targets and iii) companion diagnostics, for predicting and 
overcoming tamoxifen-resistance in different subsets of 
ER(+) breast cancer patients [14, 15]. 
RESULTS
Characterization of the metabolic phenotype of 
tamoxifen-resistant MCF-7 cell lines
In order to dissect the molecular basis of tamoxifen-
resistance that occurs during endocrine-based breast 
cancer therapy, we used tamoxifen-resistant MCF-7 
cell lines, such TAMR. The TAMR cell line is serially 
passaged in the presence of tamoxifen to maintain its 
resistance phenotype. 
First, we validated the tamoxifen-resistance 
phenotype of TAMR cells. Importantly, TAMR cells 
behaved in a tamoxifen-resistant manner and continued to 
grow, despite the presence of increasing concentrations of 
tamoxifen [16] (Figure 1)
Then, TAMR cells were subjected to metabolic 
phenotyping in order to establish their behavior. For this 
purpose, we employed the Seahorse XF96 Analyzer to 
measure metabolic flux [17, 18]. Interestingly, Figure 2 
illustrates that TAMR cells show an enhanced metabolic 
phenotype, with significant increases in oxidative 
mitochondrial metabolism and ATP production, as well 
as increased basal and maximal respiratory capacity. 
However, no significant increases in glycolytic rates 
were observed (Figure 3). This observed increase in 
ATP production was independently validated using a 
second independent biochemical assay (Figure 4A). 
Consistent with the idea that increased mitochondrial 
metabolism should lead to oxidative stress, we also found 
that the steady-state levels of reduced glutathione were 
significantly depleted (Figure 4B). Importantly, enhanced 
oxidative mitochondrial metabolism was also observed in 
a second independently-derived tamoxifen-resistant MCF-
7 cell line, known as TAMR2 (Supplemental Figure 1). 
We hypothesized that the observed increase in 
oxygen consumption and ATP production might occur 
via an increased capacity for mitochondrial biogenesis. 
In direct support of our hypothesis, TAMR cells showed 
a significant increase in both mitochondrial mass and 
mitochondrial membrane potential (Figure 5), as observed 
Figure 1: Validation of tamoxifen-resistance in TAMR cells. A. Growth curves of MCF-7-control (WT) and MCF-7-TAMR cells 
in the presence of 4-OH-Tamoxifen (4-OHT) 100nM. The arrows indicate the day that fresh growth media containing 4-OHT was added to 
the cell cultures. B. Growth responses of MCF-7-control and MCF-7-TAMR cells to increasing concentrations of 4-OHT (0.1 nM-10 µM) 
on day 2, 5 and 8 from initial treatment. The results for the graphs are expressed as the mean (+/- SD) of six wells repeated three times. * 
p < 0.01.
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by FACS analysis using MitoTracker vital dyes as probes 
(Deep Red and Orange) [19, 20]. However, this phenotype 
was strictly dependent on the presence of tamoxifen in the 
tissue culture media. 
Proteomics Analysis of TAMR Cells: NQO1 and 
GCLC are strongly up-regulated
To begin to dissect the molecular basis of this 
enhanced metabolic phenotype, TAMR cells were next 
subjected to unbiased proteomics analysis [21]. This 
would allow us to identify potential therapeutic targets 
that might confer tamoxifen-resistance. These results are 
summarized in Table 1. We focused on the top 20 proteins 
that were over-expressed in TAMR cells, relative to 
matched parental MCF-7 cells. 
Note that several of the up-regulated proteins are 
metabolic enzymes, as predicted. In this data set, we also 
noticed that the BCAS1 protein was upregulated by > 50-
fold. Importantly, BCAS1 has been previously implicated 
Figure 2: TAMR cells show a significant increase in mitochondrial oxygen consumption and mitochondrial ATP 
production. The Seahorse XF96 analyzer was employed to determine the mitochondrial function of MCF-7-control cells and MCF-7-
TAMR after 48 hours. A. A representative line graph of 3 independent experiments is shown. B. Respiration (basal and maximal), as well 
as ATP levels, were significantly increased.* p < 0.05; ** p < 0.005; *** p < 0.0005.
Figure 3: TAMR cells are more energetically active, but do not show any increases in their glycolytic rate. A. The 
Seahorse XF96 analyzer was employed to determine the status of extracellular acidification rate (ECAR) in MCF-7-control and MCF-7-
TAMR cells after 48 hours. A bar graph of 3 independent experiments is shown. ns = not significant. B. The plot of OCR versus ECAR 
shows that MCF-7-TAMR cells shift from a moderate quiescent state to a high energetic state. 
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in conferring tamoxifen-resistance. Thus, we used BCAS1 
as a positive control in some of our experiments. 
To begin to test our hypothesis that these genes 
might confer tamoxifen-resistance, we transduced 
a panel of six candidates into MCF-7 cells (NQO1, 
GCLC, ACAA2, IDH2, HSD17B4 and BCAS1) and 
Figure 4: The metabolic phenotype of TAMR cells is characterized by increased steady-state levels of ATP and 
decreased levels of reduced glutathione. A. ATP levels were evaluated with the Celltiter-Glo™ luminescent assay kit, after 24 hours 
of incubation at 37° C. B. The reduced/oxidized glutathione ratio, was evaluated with the GSH/GSSG-Glo™ Assay kit, after 24 hours of 
incubation at 37° C. Both ATP and glutathion levels were normalized by protein content (SRB) and cell number. *** p < 0.0005.
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Figure 5: Mitochondrial biogenesis and membrane potential are increased in TAMR cells, in the presence of tamoxifen. 
FACS analysis was carried out on MCF-7-control and MCF-7-TAMR cells after 72 hours. A.-B. In MCF-7-TAMR, the mitochondrial mass 
was reduced (MitoTracker Deep-Red), but an increased mitochondrial membrane potential (MitoTracker Orange) was observed after 72 
hours of incubation, in growth media 4-OHT free. C.-D. The mitochondrial mass (MitoTracker Deep-Red) and mitochondrial membrane 
potential (MitoTracker Orange) were increased after 48 hours of incubation, in growth media containing 4-OHT. **** p < 0.00001. 
Figure 6: Energetic screening in MCF-7 cells transduced with different cDNAs encoding a subset of proteins up-
regulated in TAMR cells. A. ATP levels were evaluated with the Celltiter-Glo™ luminescent assay kit, after 24 hours of incubation at 
37° C. B. The reduced/oxidized glutathione ratio was evaluated with the GSH/GSSG-Glo™ Assay kit, after 24 hours of incubation at 37° 
C. Both ATP and glutathion levels were normalized by protein content (SRB) and cell number. * p < 0.05; ** p < 0.005.
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then evaluated their metabolic phenotype. As a more 
efficient screening method, we chose to measure ATP and 
glutathione levels, to ask which of these candidates would 
be sufficient to mimic the metabolic phenotype of TAMR 
cells. As predicted, this screening method was successful 
and three out of the six candidates (BCAS1, NQO1 and 
GCLC) actually increased ATP and decreased reduced 
glutathione (Figure 6). Since NQO1 and GCLC conferred 
the largest changes in ATP and reduced glutathione, we 
decided to focus on these two metabolic enzymes as 
potential mediators of tamoxifen-resistance. NQO1 and 
GCLC were increased by 74-fold and by 29-fold in TAMR 
cells, respectively, relative to parental MCF-7 cells (Table 
1).
NQO1 and GCLC are sufficient to confer 
tamoxifen-resistance and “boost” mitochondrial 
metabolism
Based on our proteomics analysis and screening 
approach, NQO1 and GCLC emerged as the most 
promising potential targets. Thus, we subjected these 
MCF-7-NQO1 and MCF-7-GCLC cell lines to further 
characterization. We performed additional mechanistic 
studies, to determine if they truly mimic the tamoxifen-
resistance behavior and metabolic phenotype of TAMR 
cells. 
Remarkably, recombinant over-expression of NQO1 
Note that the following 5 mitochondrial and/or metabolism-related enzymes are up-regulated in MCF-7-NQO1
cells (PRDX5, SLC25A3, PKM2, MRPS22, GSR) and are highlighted in BOLD. 
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was indeed sufficient to functionally confer tamoxifen-
resistance (Figure 7). Importantly, empty-vector control 
MCF-7 cell lines tested in parallel were tamoxifen-
sensitive. Similarly, NQO1 over-expression significantly 
increased oxidative mitochondrial metabolism, with 
increased levels of ATP production and decreased levels 
Figure 7: MCF-7 cells over-expressing NQO1 are tamoxifen-resistant. A. MCF-7 cells were stably transduced with the cDNA 
encoding NQO1 or the empty vector plasmid (LV105-puro), using a lentiviral vector approach. Total cell proteins were isolated from 
transfected MCF-7 cells and analyzed by immunoblotting to confirm NQO1 expression. NQO1 antibody (#HPA007308 Sigma-Aldrich) 
was used with a dilution 1:500 in 5% of BSA. The expression of β-actin (#A2228 Sigma-Aldrich) was also assessed to ensure equal protein 
loading. B. Growth responses of MCF-7-LV105 and MCF-7-NQO1 cells to increasing concentrations of 4-OHT (0.1 nM-10µM) on day 2, 
5 and 8 from the initial treatment. The graphs are expressed as the mean (+/- SD) of six wells repeated three times. * p < 0.01.
Figure 8: NQO1 expressing MCF7 cells show a significant increase in mitochondrial oxygen consumption and 
mitochondrial ATP production. The Seahorse XF96 analyzer was employed to determine the status of mitochondrial function in 
MCF-7-LV105 cells (empty vector) and MCF-7-NQO1 cells after 48 hours. A. A representative line graph of 3 independent experiments is 
shown. B. Respiration (basal and maximal), as well as ATP levels, were significantly increased. * p < 0.05; ** p < 0.005.
Oncotarget8www.impactjournals.com/oncotarget
of reduced glutathione (Figures 8, 9 and 10). Finally, 
mitochondrial biogenesis and mitochondrial membrane 
potential were also increased in MCF-7-NQO1 cells 
(Figure 11). 
Importantly, virtually identical results were also 
obtained with GCLC. MCF-7 cells transduced with the 
cDNA of GCLC were i) tamoxifen-resistant (Figure 12) 
and ii) showed a significant increase in mitochondrial 
oxygen consumption (Figure 13 and 14). Moreover, MCF-
7-GCLC cells had enhanced ATP production and showed 
decreased reduced glutathione (Figure 15), with increased 
mitochondrial biogenesis (Figure 16). 
In accordance with the above functional data, a 
number of mitochondrial and/or other metabolism-related 
proteins were highly up-regulated, as seen by proteomics 
analysis, in both NQO1 and GCLC transfected MCF-7 
cells (Tables 2 and 3). These up-regulated mitochondrial 
proteins included ABAT, AIFM1, ATPIF1, GSR, MRPS22 
and PRDX5, among others.   
In summary, the NQO1 and GCLC genes are both 
indeed sufficient to confer tamoxifen-resistance and to 
“boost” mitochondrial metabolism. Conversely, we also 
observed that treatment of MCF-7-TAMR cells with 
dicoumarol, a known NQO1 inhibitor, reverses their 
tamoxifen-resistance phenotype (Supplemental Figures 
2 and 3). Thus, pharmacological inhibition of NQO1 and 
GCLC may be new therapeutic strategies for overcoming 
tamoxifen-resistance in breast cancer patients.
Note that the following 5 mitochondrial and/or metabolism-related enzymes are up-regulated in MCF-7-GCLC 
cells (AIFM1, ATPIF1, G6PD, PGK2, ABAT) and are highlighted in BOLD. 
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Overview of proteins and pathways identified as 
differentially regulated in the lysates of TAMR, 
NQO1 and GCLC cells relative to control MCF-
7 cells and MCF-7-LV105 (empty vector), by 
ingenuity pathway analysis
From all the proteomics data sets, the differentially 
expressed proteins were subjected to Ingenuity Pathway 
Analysis (IPA) to determine possible alterations in 
canonical pathways and toxicity functions. IPA was able 
to analyze 1,283 proteins in MCF-7-TAMR, 399 proteins 
in MCF-7-NQO1 and 684 proteins in MCF-7-GCLC cells, 
as compared with their respective controls. This analysis 
revealed that 142 proteins were differentially regulated in 
all 3 different cell lines (Figure 17A). A higher presence 
of antioxidant response proteins was further confirmed 
using IPA, which revealed the Nrf2-mediated antioxidant 
response to be one of the top canonical pathways affected. 
Similarly, TAMR, NQO1 and GCLC cells all showed very 
Figure 9: NQO1 expressing MCF7 cells are more energetically active, and show a minor increase in their glycolytic 
rate. A. The Seahorse XF96 analyzer was employed to determine the status of extracellular acidification rate (ECAR) in MCF-7-LV105 
and MCF-7- NQO1 cells after 48 hours. A bar graph of 3 independent experiments is shown. B. The plot of OCR versus ECAR shows that 
MCF-7-TAMR cells shift from moderate quiescent state to a high energetic state. * p < 0.05.
Figure 10: The metabolic phenotype of NQO1 expressing MCF7 cells is characterized by increased steady-state levels 
of ATP and decreased levels of reduced glutathione. A. ATP concentration levels, evaluate with Celltiter-Glo™ luminescent assay 
kit, after 24 hours of incubation at 37° C. B. Reduced/oxidized glutathione ratio, evaluate with GSH/GSSG-Glo™ Assay kit, after 24 hours 
of incubation at 37° C. Both types of experiments were standardized by protein content (SRB) and cell number. ** p < 0.005.
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Figure 11: Mitochondrial biogenesis and membrane potential are increased in NQO1 expressing MCF7 cells, in the 
presence of tamoxifen. FACS analysis was carried out on MCF-7-LV105 (empty vector) and MCF-7-NQO1 after 72 hours. A.-B. In 
MCF-7-NQO1, the mitochondrial mass was increased (MitoTracker Deep-Red), but not significant changes in mitochondrial membrane 
potential (MitoTracker Orange) were observed after 72 hours of incubation, in growth media 4-OHT free. C.-D. The mitochondrial mass 
(MitoTracker Deep-Red) and mitochondrial membrane potential (MitoTracker Orange) were increased after 48 hours of incubation, in 
growth media containing 4-OHT. ** p < 0.001; **** p < 0.00001.
Figure 12: MCF-7 cells harboring GCLC show tamoxifen-resistance. Growth responses of MCF-7-LV105 (empty vector) and 
MCF-7-GCLC cells to increasing concentrations of 4-OHT (0.1 nM-10µM) on day 2, 5 and 8 from initial treatment. The results for the 
graphs are expressed as the mean (+/-SD) of six wells repeated three times. * p < 0.01.
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Figure 13: MCF7 cells harboring GCLC show a significant increase in mitochondrial oxygen consumption and 
mitochondrial ATP production. The Seahorse XF96 analyzer was employed to determine the mitochondrial function of MCF-7-
LV105 (empty vector) and MCF-7-GCLC cells after 48 hours. A. A representative line graph of 3 independent experiments is shown. B. 
Respiration (basal and maximal), as well as ATP levels, were significantly increased.** p < 0.005; *** p < 0.0005.
Figure 15: MCF7 cells harboring GCLC are characterized by increased steady-state levels of ATP and decreased levels 
of reduced glutathione. A. ATP levels evaluated with the Celltiter-Glo™ luminescent assay kit, after 24 hours of incubation at 37° C. 
B. The reduced/oxidized glutathione ratio was evaluated with the GSH/GSSG-Glo™ Assay kit, after 24 hours of incubation at 37° C. Both 
assays were normalized by protein content (SRB) and cell number. ** p < 0.005.
Figure 14: MCF7 cells harboring GCLC are more energetically active, and show a minor increase in their glycolytic 
rate. The Seahorse XF96 analyzer was employed to determine the status of extracellular acidification rate (ECAR) in MCF-7-LV105 
(empty vector) and MCF-7-GCLC cells after 48 hours. A bar graph of 3 independent experiments is shown. B. The plot of OCR versus 
ECAR shows that MCF-7-TAMR cells shift from moderate quiescent state to a high energetic state. * p < 0.05.
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similar regulation of numerous cellular pathways (Figure 
17B). Importantly, the Heat-Map shows how the different 
cell lines behave almost in the same way, emphasizing 
their similarities also in the regulation of numerous cancer-
related signaling pathways. Thus, our proteomics analysis 
clearly detects alterations in mitochondrial function, the 
Nrf-2-mediated oxidative stress response and Hypoxia-
Inducible factor (HIF) signaling, all mediated by NQO1 
and GCLC as compared with MCF-7-TAMR cells (Figure 
18).
Bioinformatic validation of the clinical relevance 
of NQO1 and GCLC in human breast cancer 
patients, in various ER(+) epithelial sub-types
To assess the possible clinical relevance of NQO1 
and GCLC, we determined if their mRNA levels showed 
any prognostic value in human breast cancer patient 
cohorts, with long-term follow-up (nearly 20 years). The 
prognostic value of NQO2 was also evaluated in parallel, 
for comparison purposes. We restricted our analysis to 
ER(+) patients that received endocrine therapy (mostly 
tamoxifen), but not any form of chemotherapy. 
These results are summarized in Table 4, and in 
Supplemental Tables S1 and S2. Corresponding Kaplan-
Meier (K-M) analysis curves are included in Figure 19, 
and as Supplemental Figures 4 and 5 (panels A-D). 
Note that high mRNA expression levels of all three 
distinct NQO1 probes showed an association with reduced 
relapse-free survival (RFS, i.e., higher tumor recurrence). 
More specifically, NQO1 had prognostic value in Luminal 
A patients with lymph node metastasis (LN(+)), as well 
in Luminal B patients, and in the total ER(+) patient 
population. GCLC only showed prognostic value in 
Figure 16: Mitochondrial biogenesis and membrane potential are increased in MCF7 cells harboring GCLC, in the 
presence of tamoxifen. FACS analysis was carried out on MCF-7-LV105 (empty vector) and MCF-7-GCLC after 72 hours. A.-B. In 
MCF-7-GCLC, the mitochondrial mass was increased (MitoTracker Deep-Red), but no significant change in mitochondrial membrane 
potential (MitoTracker Orange) was observed after 72 hours of incubation, in growth media 4-OHT free. C.-D. Both the mitochondrial 
mass (MitoTracker Deep-Red) and mitochondrial membrane potential (MitoTracker Orange) were highly increased after 48 hours of 
incubation, in growth media containing 4-OHT. *** p < 0.0001; **** p < 0.00001.
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Figure 17: Overview of proteins and pathways identified as differentially regulated in the lysates of TAMR, NQO1 
and GCLC cells relative to control MCF7 cells, by Ingenuity Pathway Analysis. A. Venn diagram. Overlap of differentially 
regulated proteins identified in MCF-7-TAMR, MCF-7-NQO1 and MCF-7-GCLC, compared with their proper controls. Of all the proteins 
identified by quantitative proteomics, 142 were proteins that the expression of which was found to be altered in both treatments, compared 
to control. B. Canonical pathways identified or predicted as altered in MCF-7-TAMR, MCF-7-NQO1 and MCF-7-GCLC, relative to 
control. A positive z score is indicated in orange and points towards an activation of the pathway, and a negative z score, in blue, indicates 
an inhibition of the pathway. (T = MCF-7-TAMR vs. MCF-7-control; N = MCF-7-NQO1 vs. MCF-7-LV105; G = MCF-7-GCLC vs. MCF-
7-LV105).
Figure 18: Tox list of pathways identified as differentially regulated in the lysates of TAMR, NQO1 and GCLC cells 
relative to control MCF7 cells, by Ingenuity Pathway Analysis. Toxicity effects of differentially expressed proteins in MCF-7-
TAMR, MCF-7-NQO1 and MCF-7-GCLC compared to control cells. Ingenuity Pathway Analysis showed toxicity functions significantly 
enriched by the proteins differentially expressed in the comparison analysis (p < 0.05). In the Bar chart, the p value for each pathway is 
indicated by the bar and is expressed as -1 times the log of the p value. (T = MCF-7-TAMR Vs MCF-7-control; N = MCF-7-NQO1 Vs 
MCF-7-LV105 (empty vector); G = MCF-7-GCLC Vs MCF-7-LV105 (empty vector)).
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Recurrence-free survival (RFS) in a high-risk population of breast cancer patients:
ER(+)/Luminal A/LN(+)/EndocrineTx (mostly Tamoxifen)/N=152 patients.
Figure 19: Kaplan-Meier (K-M) analysis of the prognostic value of NQO1 and GCLC in ER(+) breast cancer patients 
receiving endocrine therapy: Luminal A subgroup. Results of recurrence-free survival analysis (RFS) are shown, over a > 15-year 
period of follow-up, for NQO1 (3 independent probes; A.-C., and GCLC D., for ER(+) breast cancer patients (N = 152) with the luminal 
A sub-type. These patients were lymph-node-positive (LN(+)) and received endocrine therapy (mostly tamoxifen), but not chemotherapy. 
Note that higher levels of NQO1 mRNA species A.-C. are significantly associated with tumor recurrence. See the Methods section for how 
the analysis was carried out. Similar results were obtained in other ER(+) sub-types of breast cancer, and are included as Supplementary 
Figures 4 and 5. 
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the Luminal B sub-population of ER(+) breast cancer 
patients. In contrast, NQO2 mRNA levels did not show 
any prognostic value in any of the ER(+) patient groups 
examined (Table 4; Supplemental Tables S1 and S2). 
Finally, since high levels of NQO1 mRNA were 
associated with disease progression in patients that 
received endocrine therapy, this is indicative of a clinical 
association with endocrine therapy-resistance. Thus, 
elevated levels of NQO1 expression could be used to 
identify high-risk ER(+) breast cancer patients, that might 
benefit from treatment with novel NQO1 inhibitors. 
DISCUSSION
In this report, we set out to identify new metabolic 
drivers of tamoxifen-resistance, by combining proteomics 
analysis with metabolic phenotyping [22, 23]. Use of 
this proteomics-metabolomics approach allowed us to 
identify enhanced mitochondrial metabolism as a key 
characteristic of TAMR cells, that was characterized 
by i) increased oxygen consumption, ii) increased ATP 
production, and iii) augmented mitochondrial biogenesis, 
as well as increased oxidative stress, as revealed by iv) 
decreased levels of reduced glutathione levels (Figure 
20). Thus, we focused the interpretation of our proteomics 
results on key metabolic enzymes that were dramatically 
increased in tamoxifen-resistant cells, such as NQO1 and 
GCLC. To determine if the over-expression of NQO1 
and/or GCLC could autonomously confer the tamoxifen-
resistance phenotype, we transduced MCF-7 cells with the 
cDNAs encoding these proteins, using a lenti-viral vector 
approach. Remarkably, NQO1 and GCLC lenti-viral 
transduction was indeed sufficient to induce tamoxifen-
resistance, as well as the metabolically-enhanced 
mitochondrial phenotype. 
Thus, increased mitochondrial function may help 
drive tamoxifen-resistance in human breast cancer cells 
(Figure 20). This key finding has important mechanistic 
implications for understanding the molecular basis of 
tamoxifen-resistance. Furthermore, the over-expression of 
NQO1 mRNA species predicted tumor recurrence in high-
risk ER(+) that were LN(+) and had received endocrine-
therapy (mostly tamoxifen), but not chemotherapy. As 
such, our findings may have translational and clinical 
relevance for over-coming the resistance to endocrine 
therapy in ER(+) breast cancer patients [24]. 
It remains unknown exactly how NQO1 and GCLC 
drive an enhanced mitochondrial metabolic phenotype. 
The NQO1 protein product is an enzyme known as 
NAD(P)H dehydrogenase [quinone] 1. It is the main non-
mitochondrial enzyme responsible for the reduction of 
CoQ10 in cells. Thus, NQO1 may “boost” mitochondrial 
metabolism by providing increased reduced CoQ10 
species to facilitate oxidative mitochondrial metabolism 
[25, 26]. 
The GCLC protein product is an enzyme known as 
glutamate-cysteine ligase catalytic subunit. Glutamate-
cysteine ligase is also known as gamma-glutamyl-
cysteine synthetase, and is the first and rate-limiting step 
for glutathione synthesis. While it remains unknown how 
GCLC regulates mitochondrial function, its deletion in 
mouse liver leads to striking decreases in mitochondrial 
function, mitochondrial injury, loss of cellular ATP, and 
a marked increase in lipid peroxidation, driving steatosis 
and liver failure. Interestingly, treatment of these mice 
with oral N-acetyl-cysteine (NAC) restores mitochondrial 
function and prevents mortality caused by the loss of 
hepatocyte GSH synthesis [27, 28].
NQO1 and GCLC are normally up-regulated as part 
of the Nrf2-anti-oxidant response, which occurs during 
oxidative stress [12, 24]. Thus, the observed up-regulation 
of NQO1 and GCLC in TAMR cells may directly reflect 
that tamoxifen treatment can induce oxidative stress. How 
does tamoxifen induce oxidative stress? Several different 
mechanisms have been proposed to explain the manner 
in which tamoxifen induces oxidative stress in cells, 
including the targeting of NOS, SOD2 and ER-beta in 
mitochondria. 
Tamoxifen also has direct effects on mitochondrial 
function. Tamoxifen acts both as an uncoupling agent 
and as a potent inhibitor of electron transport, ultimately 
leading to a collapse of the mitochondrial membrane 
potential and cellular apoptosis [29-31]. More specifically, 
tamoxifen inhibits electron transfer at the levels of both 
Figure 20: Enhanced mitochondrial metabolism: A 
new mechanism for driving tamoxifen-resistance. A 
schematic diagram is shown high-lighting our observations 
that increased mitochondrial oxygen-consumption and ATP-
production, as well as increased mitochondrial biogenesis and 
oxidative stress, all contribute to the metabolic phenotype of 
tamoxifen-resistant breast cancer cells. In this process, the over-
expression of NQO1 and GCLC appear to be key drivers of this 
phenotype.
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complex III (ubiquinol-cytochrome-c reductase) and 
complex IV (cytochrome-c oxidase). Similarly, it has also 
been reported that tamoxifen elevates mitochondrial ROS, 
mitochondrial lipid peroxidation and cytochrome c release, 
while driving the tyrosine-nitration of key mitochondrial 
proteins.
Therefore, our current findings could mechanistically 
explain why “boosting” mitochondrial metabolism may 
lead to tamoxifen-resistance in human breast cancer cells. 
If tamoxifen indeed behaves as a mitochondrial “poison”, 
then increased mitochondrial “power” could help to buffer 
against the mitochondrial toxicity effects of tamoxifen, 
thereby conferring tamoxifen-resistance. 
MATERIAL AND METHODS
Materials
MCF7 cells (catalogue # HTB-22), a human breast 
cancer cell line, were originally obtained from the ATCC 
cell repository. Tamoxifen and dicoumarol were obtained 
commercially from Sigma-Aldrich, Inc. 
Label-free semi-quantitative proteomics analysis 
Cell lysates were prepared for trypsin digestion 
by sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled to 
an Ultimate 3000 RSLCnano system (Thermo Scientific, 
formerly Dionex, The Netherlands). Xcalibur raw data 
files acquired on the LTQ-Orbitrap XL were directly 
imported into Progenesis LCMS software (Waters Corp) 
for peak detection and alignment. Data were analyzed 
using the Mascot search engine. Five technical replicates 
were analyzed for each sample type [32]. 
Ingenuity pathway analyses
Pathway and function analyses were generated 
using Ingenuity Pathway Analysis (IPA) (Ingenuity 
systems, http://www.ingenuity.com), which assists with 
proteomics data interpretation via grouping differentially 
expressed genes or proteins into known functions and 
pathways. Pathways with a z score > 1.5 were considered 
as significantly activated, and pathways with a z score < 
-1.5 were considered as significantly inhibited.
Lentiviral gene transduction
Lentiviral plasmids, packaging cells and reagents 
were purchased from Genecopoeia. 48 hours after 
seeding, 293Ta packaging cells were transfected with 
lentiviral vectors encoding NQO1 or GCLC or empty 
vector (EX-NEG-Lv105), using Lenti-PacTM HIV 
Expression Packaging Kit according to the manufacturer’s 
instructions. Two days post-transfection, lentivirus-
containing culture medium was passed through a 0.45 µm 
filter and added to the target cells (MCF-7 cells) in the 
presence of 5µg/ml Polybrene. Infected cells were selected 
with a concentration of 1.5 µg/ml of puromycin.
Cellular growth using the sulforhodamine B 
(SRB) assay
SRB (S9012, Sigma) measures total biomass by 
staining cellular proteins. After 2, 5 and 8 days, cells 
were fixed in 10% trichloroacetic acid (T9159, Sigma) 
for 1h at 4°C, stained with SRB (S9012, Sigma) for 15 
minutes, and washed 3 times with 1% acetic acid (27225, 
Sigma). The incorporated die was solubilized with 10 
mM Tris Base, pH 8.8 (T1503, Sigma). Absorbance was 
spectrophotometrically measured at 540 nm in a FluoStar 
Omega plate reader (BMG Labtech). Background 
measurements were subtracted from all values. 
Dicoumarol was obtained from Sigma-Aldrich, Inc. 
Seahorse XF96 metabolic flux analysis (OCR and 
ECAR)
Real-time oxygen consumption rates (OCR) and 
extracellular acidification rates (ECAR) measurements 
were determined using the Seahorse Extracellular Flux 
(XF96) analyzer (Seahorse Bioscience, MA, USA). 
1 x 104 cells per well were seeded into XFe-96 well 
cell culture plates, and incubated overnight to allow 
attachment. Control cells were processed in parallel. After 
48 hours of incubation, cells were washed in pre-warmed 
XF assay media (or for OCR measurement, XF assay 
media supplemented with 10mM glucose, 1mM Pyruvate, 
2mM L-glutamine and adjusted at 7.4 pH). Cells were then 
maintained in 175 µL/well of XF assay media at 37°C, in a 
non-CO
2
 incubator for 1 hour. During the incubation time, 
we loaded 25 µL of 80mM glucose, 9µM oligomycin, 
and 1M 2-deoxyglucose (for ECAR measurement) or 
10µM oligomycin, 9µM FCCP, 10µM rotenone, 10µM 
antimycin A (for OCR measurement), in XF assay media 
into the injection ports in the XFe-96 sensor cartridge. 
Data sets were analyzed by XF96 software and GraphPad 
Prism software, using one-way ANOVA and Student’s 
t-test calculations. All experiments were performed in 
quintuplicate, three times independently.
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ATP and glutathione levels
Cell activity was measured using a CellTiter-Glo™ 
assay kit (Promega, Madison, WI #G7571) and GSH/
GSSG-Glo™ Assay kit (Promega, Madison, WI #V6612) 
following the manufacturer’s protocol. For ATP detection, 
2 x 104 cells were seeded in a 96-well plate and incubated 
for 24h. After 24 hours, Celltiter-Glo reagent was added to 
each well, and the plate was incubated at room temperature 
for 10 minutes with constant shaking before detected the 
luminescence intensity. For GSH/GSSH ratio content, 1 
x 104 cells were seeded in a 96-well plate and incubated 
for 24h. After 24 hours, Total and Oxidized Glutathione 
reagents were added to each well and incubated for 30 
minutes. Luciferin was added to each well and the plate 
was read after 15 minutes. Luminescence intensity was 
read using a FluoStar Omega plate reader (BMG Labtech) 
taking the luminescence reading of control as the 100% 
value. Background measurements were subtracted from 
all values. The experiments were performed using 4 x 104 
cells also and 48 hours of incubation. The results followed 
the same trend (data not shown). All experiments were 
performed in sixtuplicate, four times independently.
Mitochondrial staining
Mitochondrial activity was assessed with 
MitoTracker Orange (#M7510, Invitrogen), whose 
accumulation in mitochondria isdependent upon 
membrane potential. Mitochondrial mass was determined 
using MitoTracker Deep-Red (#M22426, Invitrogen), 
localizing to mitochondria regardless of mitochondrial 
membrane potential. 2 x 105 cells were seeded in a 6 well 
plate and leave at 37°C for 72 hours. Control cells were 
processed in parallel. After 72 hours, cells were incubated 
with prewarmed MitoTracker staining solution (diluted 
in PBS/CM to a final concentration of 10 nM) for 30-60 
minutes at 37°C. All subsequent steps were performed 
in the dark. Cells were washed in PBS, harvested, and 
re-suspended in 300 μL of PBS/CM. Cells were then 
analyzed by flow cytometry. Data analysis was performed 
using FlowJo software.
Statistical analysis
Data is represented as the mean ± standard deviation 
(SD), taken over ≥ 3 independent experiments, with ≥ 3 
technical replicates per experiment, unless otherwise 
stated. Statistical significance was measured using the 
analysis of variance (ANOVA) test or student t-test. P ≤ 
0.05 was considered significant and all statistical tests were 
two sided. Mitochondrial staining dats are represented 
as the mean ± standard deviation (SEM), taken over ≥ 3 
independent experiments, with ≥ 3 technical replicates 
per experiment, unless otherwise stated. Statistical 
significance was measured using the analysis of variance 
(ANOVA) test. P ≤ 0.05 was considered significant and all 
statistical tests were two sided.
Kaplan-meier (K-M) analysis
To perform K-M analysis on NQO1, NQO2 and 
GCLC gene transcripts, we used an open-access online 
survival analysis tool to interrogate publically available 
microarray data from > 5,000 breast cancer patients. This 
allowed us to determine their prognostic value. For this 
purpose, we primarily analyzed data from ER(+) patients 
that were LN(+) at diagnosis and were of the luminal 
A sub-type, that were primarily treated with tamoxifen 
and not other chemotherapy (N = 152 patients). Biased 
and outlier array data were excluded from the analysis. 
Hazard-ratios were calculated, at the best auto-selected 
cut-off, and p-values were calculated using the logrank test 
and plotted in R. K-M curves were also generated online 
using the K-M-plotter (as high-resolution TIFF files), 
using univariate analysis: http://kmplot.com/analysis/
index.php?p = service&cancer = breast. This allowed us 
to directly perform in silico validation of these biomarker 
candidates. The most updated version of the database was 
utilized for all these analyses.
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